Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sifalimumab in Systemic Lupus Erythematosus
NCT01283139Phase 2Completed
- Sponsor
- MedImmune
- Start
- Mar 2011
- Primary completion
- Nov 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 2 trial of sifalimumab in systemic lupus erythematosus (SLE), sponsored by MedImmune. Started Mar 2011; status: completed.
02
Drugs
sifalimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01283139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01283139.